The authors found that Miro-1 was upregulated in the stroma of liver, breast, and ovarian cancers and that Miro-1 and mDia2 co-expression in liver and lung cancers, which indicates increased migration activity, was associated with decreased patient survival. Here, RHOT1 is linked to ovarian cancer.